b x0cinnovative bioresearch milan italy http www innovativebioresearch com x0cdisclaimer liability review carefully present section xe2 x80 x9cdisclaimer liability xe2 x80 x9d doubts actions recommend consult legal financial tax professional advisor s whitepaper reproduced distributed disseminated including section xe2 x80 x9cdisclaimer liability xe2 x80 x9d sole purpose whitepaper present innovative bioresearch innbc tokens potential token holders connection proposed token sale information provided information purposes exhaustive doesn xe2 x80 x99t imply elements contractual relationship obligations despite fact effort ensure accuracy date relevance material whitepaper document materials contained professional advice way constitutes provision professional advice kind innovative bioresearch reserves right modify update whitepaper information contained moment notice maximum extent permitted applicable laws regulations rules innovative bioresearch doesn xe2 x80 x99t guarantee doesn xe2 x80 x99t accept legal responsibility nature indirect special incidental consequential losses kind tort contract including limited loss revenue income profits loss use data arising related accuracy reliability relevance completeness material contained whitepaper innovative bioresearch purport disclaims representation warranty undertaking form whatsoever entity person authority including representation warranty undertaking relation truth accuracy completeness information set whitepaper contact relevant independent professional advisors relying making commitments transactions based material published whitepaper whitepaper subject legal system governed law regulatory authority examined approved information set whitepaper action taken laws regulatory requirements rules jurisdiction publication distribution dissemination whitepaper imply applicable laws regulatory requirements rules complied don xe2 x80 x99t right shouldn xe2 x80 x99t buy innbc tokens green card holder united states america ii citizen resident tax united states america puerto rico virgin islands united states possessions united stated america singapore people xe2 x80 x99s republic china south korea person states iii citizen resident tax country territory transactions digital tokens digital currencies prohibited manner restricted applicable laws xe2 x80 x9cperson xe2 x80 x9d generally defined natural person residing relevant state entity organized incorporated laws relevant state purchased tokens offered distributed resold alienated holders mentioned persons sole responsibility establish consulting necessary legal tax accounting professional advisors requirements limitations apply particular jurisdiction ensure observed complied restrictions expense liability innovative bioresearch innovative bioresearch milan italy http www innovativebioresearch com x0cinnbc tokens intended constitute securities digital currency commodity kind financial instrument registered relevant securities regulations including securities laws jurisdiction potential token holder resident whitepaper prospectus proposal purpose serve securities offer request investments form securities jurisdiction spite legislation certain jurisdictions future recognize innbc tokens securities innovative bioresearch accept liability recognition legal consequences recognition potential owners innbc tokens provide opinions advice acquisition sale operations innbc tokens fact provision whitepaper doesn xe2 x80 x99t form basis relied matters related conclusion contracts acceptance investment decisions whitepaper doesn xe2 x80 x99t oblige enter contract legal obligations respect sale purchase innbc tokens accept crypto currency form payment potential owners innbc tokens advised contact relevant independent professional advisors matters certain statements estimates financial information contained constitute forward looking statements information forward looking statements information involve known unknown risks uncertainties cause actual events results differ materially estimates results implied expressed forward looking statements examples calculation income profits whitepaper provided demonstration purposes demonstrating industry s averages avoidance doubt contained whitepaper relied guarantee promise representation undertaking future performance innovative bioresearch innbc token promise guarantee future profit resulting purchase innbc token innbc tokens purposes provided whitepaper including limited investment speculative financial purposes innbc tokens confer rights form including limited ownership distribution including limited profit redemption liquidation property including forms intellectual property financial legal rights specifically set forth community s opinion feedback taken account innbc tokens right participate decision making direction business related innovative bioresearch service english language whitepaper primary official source information innbc tokens information contained time time translated languages course written oral communications customers contractors partners etc course translation communication information contained lost corrupted misrepresented event conflicts inconsistencies translations communications english language whitepaper provision english language whitepaper original document shall prevail continuing reading whitepaper confirm read understood accepted agreed section disclaimer liability innovative bioresearch milan italy http www innovativebioresearch com x0ccontent page 6 page 9 page 14 page 16 page 23 page 24 page 29 aids cure research blockchain implementation app social features token utility timeline business model team innovative bioresearch milan italy http www innovativebioresearch com x0cour aids cure research innovative bioresearch privately held biotech company based italy http www innovativebioresearch com owned founded research scientist jonathan fior goal bringing innovation field focus hiv cancer regeneration research launching token sale supporting aids acquired immunodeficiency sindrome associated hiv infection cure research develop application providing hand decentralized database clinical data generated future human trials overcome limitations current ancient centralized databases hand social platform hiv seropositive community future services let xe2 x80 x99s start focusing goal token sale support aids cure research overview current state supt1 cell infusion therapy novel cell based therapy hiv conceived jonathan fior owner chief scientific officer innovative bioresearch supt1 cell infusion novel cell basede therapy hiv hiv infection usually leads progressive decline number functionality cd4 t lymphocytes resulting aids development explained jonathan fior xe2 x80 x99s scientific publications 1 xe2 x80 x933 hiv virus higher tropism supt1 cells primary cd4 t cells hypotheses proposed explanation notably higher surface expression cd4 cxcr4 receptors supt1 cells addition vitro studies hiv evolution persistent growth supt1 cell line results cytopathic virus reduced capacity syncytium formation higher sensitivity neutralization improved replication supt1 cells impaired infection primary cd4 t cells 4 xe2 x80 x936 accordingly jonathan fior proposed infusion irradiated supt1 cells cell based hiv therapy exploit therapeutic potential phenomena 1 xe2 x80 x933 rationale approach moving infection inoculated cells prevent infection depletion patient xe2 x80 x99s cd4 t cells aids strategy supt1 cells act xe2 x80 x9cdecoy target xe2 x80 x9d hiv virus prevent cd4 t cell depletion render virus cytopathic previously mentioned vitro studies hiv evolution prolonged replication supt1 cells renders virus cytopathic sensitive neutralization accordingly replication virus inoculated supt1 cells vaccination effect therapy induce virus progressively aggressive harmful patient use supt1 cells decoy target hiv investigated vitro vivo interesting results 1 3 vitro data showed primary cd4 t cells infected hiv presence supt1 cells preferential infection supt1 cells spare primary cd4 t cells infection depletion vivo data humanized mice showed significantly lower viral replication 10 fold potentially preserved cd4 t cell frequency week 1 scored animals treated supt1 cell infusion note animal exhibited sustained decrease hiv replication cd4 t cell depletion virus detected anymore weeks 3 4 result hold key future hiv treatments given urgent global need cost effective cure hiv believe millions people infected innovative bioresearch milan italy http www innovativebioresearch com x0cterrible disease deserve highly innovative hiv cure research strategies supt1 cell infusion therapy summary potential therapeutic benefits cell based treatment achievable traditional drug based therapies cart xe2 x80 xa2the vaccination effect previously mentioned supt1 cells shown powerful vaccination effect vitro 4 xe2 x80 x936 regard vitro studies hiv evolution showed prolonged replication supt1 cells x4 hiv 1 lai virus evolves virulent phenotype reduced capacity syncytium formation losing main cytopathic feature characterizing x4 strains notably virus adaptation replicate supt1 cells results gradually losing ability replicate primary cd4 t cells 4 addition variation neutralization sensitivity viral growth tumor t cell lines examined interestingly study reported primary isolates initially resistant neutralization acquired sensitivity neutralization continuous growth tumor t cell lines sensitivity neutralization progressively increased days culturing 5 specifically shown 14 days continuous culture 100 micrograms ml rscd4 recombinant soluble cd4 needed neutralize 1 tcid primary isolate 0 3 micrograms ml rscd4 needed neutralize 1 tcid virus 75 days continuous culture means 300 fold increase virus sensitivity neutralization prolonged replication tumor t cell line remarkable phenomena harbor significant therapeutic potential exploited supt1 cell infusion therapy induce hiv infection evolve tractable state therapy xe2 x80 xa2potentially organ toxicity cart drug based treatment associated organ toxicity drugs metabolized organs contrast supt1 cell infusion cell based treatment chemical substance injected body needs metabolized significantly improve quality patient s life xe2 x80 xa2be effective patients terminal state disease developed drug resistant aggressive hiv strains patient treated cart virus fights strives survive result development aggressive drug resistant hiv strains especially terminal stage disease cases cart ineffective contrast supt1 cell infusion therapy provides virus permissive cell line preferentially replicate peaceful coexistence virus host possible dramatically improve patient s health virus infection progressively moves inoculated supt1 cells virus increasingly pathogenic host xe2 x80 xa2possible association treatment novel molecular compounds vif inhibitor act hiv reservoirs hiv 1 vif protein essential viral replication primary cd4 t cells supt1 cells 1 accordingly pharmacologic inhibition vif combined supt1 cell infusion restrict viral replication inoculated supt1 cells considering apobec3g expressed different cell types neuronal cells astrocytes macrophages 2 innovative bioresearch milan italy http www innovativebioresearch com x0cpharmacologic inhibition vif benefit acting hiv reservoirs brain body areas molecules promising anti vif activity currently tested 2 similarly hiv 1 accessory proteins essential replication supt1 cells e g vpr vpu nef 3 target pharmacologic inhibition important point drugs affect virus replication inoculated supt1 cells combination supt1 cell infusion therapy development drug resistance normally associated drug based treatments xe2 x80 xa2a cost effective aids cure solution mission provide cost effective cure solution aids contrast traditional cell based gene based therapies use modified autologous cells expensive unpractical large scale application standardized t cell line supt1 cell line significantly reduce treatment costs associated supt1 cell infusion therapy allowing access therapy access traditional hiv therapies restricted economic social limitations social economical impacts low cost hiv cure solution enormous considerations regard potential issues xe2 x80 xa2safety issue seriously committed performing rigorous preclinical research ensure data safety obtain approval regulatory agencies human experimentation regard injection irradiated tumor cells therapy performed cancer vaccination cases irradiating cells prior inoculation shown ensure treatment safety animal clinical studies 7 protocol cancer vaccination studies e 30 gy radiation dose cells resulted safe vivo inoculation animal study 3 specifically animals successfully survived treatment presence supt1 cells undetectable late time points means irradiating cells prior inoculation efficiently prevented supt1 cell replication furthermore infused high doses cells 40 million supt1 cells infused weekly highly immunodeficient mouse strain rapidly lead animal death case tumor development based clinical data cancer vaccination studies results animal study believe meeting safety standards required human trials feasible xe2 x80 xa2rejection issues tumors develop tumor cells able evade immune recognition example supt1 cells express hla dr antigen highly associated immune recognition 8 accordingly given tumoral nature supt1 cells significantly immunogenic normal cells survive patient long provide therapeutic effect possible hiv virus eradicate cells faster efficiently immune system case innovative bioresearch milan italy http www innovativebioresearch com x0creferences 1 fior j initial vitro investigation potential therapeutic use supt1 cells prevent aids hiv seropositive individuals plos 2012 7 13 https www ncbi nlm nih gov pmc articles pmid 22701517 2 fior j pacific coexistence virus host unexploited path lead hiv functional cure viruses 2013 5 753 xe2 x80 x93757 https www ncbi nlm nih gov pmc articles pmid 23430684 3 fior j supt1 cell infusion possible cell based therapy hiv results pilot study hu pbmc brgs mice vaccines 2016 4 13 https www ncbi nlm nih gov pmc articles pmid 27128948 4 das t land braakman klaver b berkhout b hiv 1 evolves nonsyncytiuminducing virus prolonged culture vitro virology 1999 263 55 xe2 x80 x9369 https www ncbi nlm nih gov pubmed 10544082 5 turner s tizard r demarinis j pepinsky r b zullo j schooley r fisher r resistance primary isolates human immunodeficiency virus type 1 neutralization soluble cd4 lower affinity viral envelope glycoprotein gp120 proc natl acad sci usa 1992 89 1335 xe2 x80 x931339 https www ncbi nlm nih gov pubmed 1741386 6 moore j p burkly l c connor r cao y tizard r ho d d fisher r adaptation primary human immunodeficiency virus type 1 isolates growth transformed t cell lines correlates alterations responses envelope glycoproteins soluble cd4 aids res hum retroviruses 1993 9 529 xe2 x80 x93539 https www ncbi nlm nih gov pubmed 8347397 7 salgia r et al vaccination irradiated autologous tumor cells engineered secrete granulocyte macrophage colony stimulating factor augments antitumor immunity patients metastatic non small cell lung carcinoma j clin oncol 2003 21 624 xe2 x80 x93630 https www ncbi nlm nih gov pubmed 12586798 8 dufresne et al targeting lymph nodes liposomes bearing anti hla dr fab xe2 x80 xb2 fragments biochim biophys acta 1999 1421 284 94 https www ncbi nlm nih gov pubmed 10518698 let xe2 x80 x99s talk application starting function providing decentralized databese clinical data challenge having access clinical data current ancient centralized databases traditionally data generated scientific research collected form scientific article published peer reviewed scientific journal usually available public database nih xe2 x80 x99s pubmed database https www ncbi nlm nih gov pubmed novel therapeutic strategy supt1 cell infusion therapy goes stages clinical research different research teams world perform research therapy finally approved human treatment different clinicians world administer treatment patients means research team wants perform clinical research tedious time consuming process searching published data innovative bioresearch milan italy http www innovativebioresearch com x0cfrom previous trials read papers select useful data best possible interpretation data create protocol trial personalizing typology patients fact patient different individual characteristics e g age ethnicity hiv tropism require personalized treatment protocols issue present clinicians begin administer approved treatment patients papers best guess treatment protocol mentioned process accessing clinical data tedious time consuming introduce human error possible solution decentralized database blockchain store access clinical data possible solution challenge posed having access clinical data current ancient system provided creation decentralized database clinical data blockchain technology proposing creation xe2 x80 x9cyou xe2 x80 x99re xe2 x80 x9d application let xe2 x80 x99s focus blockchain aspect app explain later xe2 x80 x9cyou xe2 x80 x99re xe2 x80 x9d app feature user friendly interface allowing clinician innovative bioresearch milan italy http www innovativebioresearch com x0crunning clinical investigation enter data produced trials application allow input broad range individual parameters treated patient age ethnicity disease progression stage viral tropism hiv virus carried clinical protocol e g dosage supt1 cells infused week outcome treatment e g viral load cd4 t cell count app access elaborate data fly statistical analysis means standard deviations correlations power elaboration suggested treatment profiles work best type patient performed away burden having manually search process data current centralized databases involves printing hundreds papers application infinite potential growing instance amazing feature store database genotypic information hiv virus carried patient allowing track mutations genetic modifications caused treatment resulting viral phenotypic changes database constantly growing evolving new parameters added available anytime connected important aspect usually scientific publication raw data published instead graphical representation summarize data amazing feature decentralized database having editorial constraints scientific journal raw data generated research included database app help speed tremendously clinical development stages aids cure research game changer publish data traditional peer reviewed system reviewed published data immediately available easy access application potential advantages blockchain technology creating decentralized database clinical data xe2 x80 xa2immutability scientific data need immutable study peer reviewed published data permanently stored altered blockchain data stored single node ceasing exist staying blockchain immutability gives blockchain openness bft byzantine fault tolerance xe2 x80 xa2decentralization blockchain designed distributed synchronized networks making data freely available believe scientific data shared hidden firewall xe2 x80 xa2security kind transactions performed strictly defined advance stored blockchain xe2 x80 x9csmart contracts xe2 x80 x9d prevents fraudulent data added blockchain ensuring integrity database contrast easier compromise centralized database innovative bioresearch milan italy http www innovativebioresearch com x0chere potential drawbacks xe2 x80 xa2transaction slowness bitcoin limit 7 transactions second etherum 15 limit applications require thousands million database transactions second hardly case scientific database data entered slower pace given require moths years clinical study completed new data produced xe2 x80 xa2data storage primitive blockchain uses primitive key value database problem applications storing complex databases scientific data consist simple sets alphanumeric data easily stored blockchain compressing storing hexadecimal format innovative bioresearch milan italy http www innovativebioresearch com x0cwe planning use application specifically aids cure research overcome limitations current centralized databases believe interest application parties application designed research scientist research scientists database open company institution interested app storing clinical data encourage believe scientific data shared publicly let xe2 x80 x99s explain named application xe2 x80 x9cyou xe2 x80 x99re xe2 x80 x9d application document progress aids cure research project featuring periodic updates articles vlogs create community hiv seropositive people stay date comment share interact working cure creates bridge hiv seropositive people research scientists working cure allows hiv seropositive community interested journey send message battle fighting care message hope vision intention create application act social app hiv seropositive people participate create new topics discussions support stand fight aids innovative bioresearch milan italy http www innovativebioresearch com x0c xe2 x80 x9cyou xe2 x80 x99re xe2 x80 x9d social features application provide official channel patients able access therapy providing information ongoing clinical trials participate hiv treatment approved provide information clinics hospitals offering treatment book appointments legit clinicians officially collaborating offer best services rates innovative bioresearch milan italy http www innovativebioresearch com x0cinnovative bioresearch milan italy http www innovativebioresearch com x0ctoken utility intrinsic value token convert tokens physical goods tokens usually backed value actual real physical goods means stopping falling value trust platform wanted provide token holders wanted token backed value physical good innovative bioresearch love jdm cars let xe2 x80 x99s face imports beat muscle cars stage right end token sale launch innbc jdm online garage innbc tokens spent buy cars selection high quality jdm classic cars selection cars concentrate classic iconic jdm cars skylines supras subaru evos wonderfully comes jdm cars founder jonathan fior great expertise personally involved business importing years established solid network professional contacts makes confident providing quality service innovative bioresearch milan italy http www innovativebioresearch com x0cwe offer amazing deals garage providing worldwide shipping contrast tokens market innbc token value backed value real physical goods jdm cars help innbc token hold value jdm cars online garage selection high quality examples mint conditions cars going value true collector items investment common cars buy dealer hard find hunting good examples source japan innovative bioresearch milan italy http www innovativebioresearch com x0cinnovative bioresearch milan italy http www innovativebioresearch com x0cnote cars prices listed indication provide general picture final product jdm cars biomedical research related project simply awesome isn xe2 x80 x99t access providing service customers thanks founder xe2 x80 x99s community car enthusiast community welcoming sensitive community comes supporting social issues fighting aids believe having classic iconic jdm cars backing value innbc tokens true spirit project solve global health problem addition automotive industry responsive believe possible future wonderful partnerships expanding token economy making constantly growing successful believe innovative bioresearch milan italy http www innovativebioresearch com x0cthat providing straightforward utility e directly use token buy physical goods fiat currency seriously help reaching customers normally crypto world second stage 3 6 months token sale launch version xe2 x80 x9cyou xe2 x80 x99re xe2 x80 x9d app innbc tokens spent access number privileged features app ecosystem moderator social communities 1% revenue generated app ads community moderators compensation work addition token economy integral rep reward point system social community users particularly useful contributions earn tokens innovative bioresearch milan italy http www innovativebioresearch com x0cinnovative bioresearch milan italy http www innovativebioresearch com x0ctoken sale details 1 2 3 4 hard cap payment methods number innbc pre sale number innbc sale 50million innbc tokens including pre sale eth 20 000 000 30 000 000 innbc token erc20 token released etherum blockchain initial limited supply innbc tokens innovative bioresearch intends use funds received token sale development project payment salaries future expenses help accelerate development enable team work time total commitment tokens sold actually minted end token sale meaning total supply consist sold tokens plus tokens reserved innovative bioresearch innovative bioresearch reserve 100 000 000 tokens supporting token economy tokens available sale innbc token purchased innbc tokens distributed purchasers holders innbc tokens free sell tokens users need access platform innbc pricing innbc token emission price 1eur 1 23usd 1innbc corresponding 415innbc 1eth respect eth eur exchange rate day smart contract creation 16 april 2018 minimum purchase 10 innbc tokens token sale offer following discounts xe2 x97 x8f20% discount pre sale 498innbc 1eth xe2 x97 x8f10% discount successive sale 456innbc 1eth innovative bioresearch milan italy http www innovativebioresearch com x0ctimeline xe2 x97 x8ftoken pre sale expect launch pre sale beginning 2018 pre sale 1 5 months xe2 x97 x8ftoken sale sale place shortly pre sale expect launch sale mid june 2018 1 5 months xe2 x97 x8fjdm online garage online garage launched shortly token sale expect ready beginning august 2018 xe2 x97 x8faids research start contracting partners perform preclinical animal research supt1 cell infusion therapy immediately token sale completion expect start animal research october 2018 complete december 2019 expect start human trials mid 2020 conclude human experimentation phase 1 2 3 trials 5 8 years expect supt1 cell infusion therapy commercially available 2025 2028 xe2 x97 x8fyou xe2 x80 x99re app expect launch application 3 6 months token sale ends expect launch november 2018 february 2019 innovative bioresearch milan italy http www innovativebioresearch com x0cbusiness model assume source revenue represented app ads car sales innbc jdm online garage successive source revenue hiv therapy approval commercialization revenues dependant rpm turn highly variable depends factors traffic crt click rate cpc cost click average rpm low 0 5$ broad niches high 100$ competitive niches narrow nice hiv seropositve community estimated platform ads specific hiv related producs e g prep medications seronegative partner generating average rpm 66$ 25k visits day generate roughly 50k$ month key aim highly targeted audience resulting greater relevancy rpm innovative bioresearch milan italy http www innovativebioresearch com x0cadditional revenue generated sponsorship programs automotive industry want use store sell advertise products innovative bioresearch milan italy http www innovativebioresearch com x0cthere 36 7million people infected hiv globally 2016 17 5million left untreated according unaids mission develop low cost cell based therapy solution hiv allow access treatment individuals normally left untreated social economic limitations estimate treatment significantly cheaper antiretroviral therapy art conventional drug based therapy hiv substantially cheaper gene therapy product modified autologous cells offered competitors innovative bioresearch milan italy http www innovativebioresearch com x0c 1 source gebo ka fleishman ja et al contemporary costs hiv healthcare haart era aids 2010 24 2705 15 2 estimated based complexity costly operations required produce administer gene therapy autologous cell products hiv stan r zaia ja practical considerations gene therapy hiv cure curr hiv aids rep 2014 11 11 9 3 estimated based previous experience propagating administering supt1 cells humanized mice fior j supt1 cell infusion possible cell based therapy hiv results pilot study hu pbmc brgs mice vaccines 2016 4 13 potential target 36 7million hiv infected individuals globally aids cure solution generate 9billion year revenue successfully targeting 20% global hiv infected population therapy prove safe effective hiv cure believe realistic goal innovative bioresearch milan italy http www innovativebioresearch com x0c xe2 x80 xa2app tech development funds develop application expect launch 6 months ico xe2 x80 xa2app maintenance funds devoted general maintenance application live running xe2 x80 xa2ecosystem development funds devoted creating infrastructures support app e g integrating app information systems hospitals clinics partnering administering hiv therapy promotion app community e marketing costs xe2 x80 xa2jdm car stock funds devoted maintaining constant stock cars jdm online garage xe2 x80 xa2aids cure research funds devoted developing supt1 cell infusion therapy includes preclinical animal research human trials phase 1 2 3 innovative bioresearch milan italy http www innovativebioresearch com x0cteam jonathan fior owner chief scientific officer jonathan fior research scientist specialized field virology immunology cancer regeneration founded innovative bioresearch conceived supt1 cell infusion therapy novel cell based therapy hiv uses supt1 cells decoy target hiv 1 prevent cd4 t cell depletion render virus cytopathic jonathan fior successful stock trader great financial competence science biggest passions jdm classic cars 90s skylines supras led involved business importing davide bosetti social media manager davide bosetti social media expert responsible social community related aspects projects innovative bioresearch innovative bioresearch milan italy http www innovativebioresearch com x0calessandro gatti chief legal officer alessandro gatti legal expert ensures accordance law jonathan fior publications fior j initial vitro investigation potential therapeutic use supt1 cells prevent aids hiv seropositive individuals plos 2012 7 5 e37511 https www ncbi nlm nih gov pmc articles pmid 22701517 fior j pacific coexistence virus host unexploited path lead hiv functional cure viruses 2013 5 2 753 7 https www ncbi nlm nih gov pmc articles pmid 23430684 fior j salamander regeneration model developing novel regenerative anticancer therapies j cancer 2014 5 8 715 9 https www ncbi nlm nih gov pmc articles pmid 25258653 fior j supt1 cell infusion possible cell based therapy hiv results pilot study hu pbmc brgs mice vaccines 2016 4 2 13 https www ncbi nlm nih gov pmc articles pmid 27128948 innovative bioresearch milan italy http www innovativebioresearch com x0chow operate research projects jonathan fior works pi principal investigator conceiving experiments writing experiment protocol work commissioned contract research organization cro physically performs experiments jonathan fior supervises aspects related research communicating closely cro experiments completed analyzes results writes scientific paper published peer reviewed scientific journal publish open access scientific journals believe free information don xe2 x80 x99t want data hidden paywall means team big team actually companies 100 people working team need large way small strong great team maximize results reducing costs perform highly specialized research partnering state art cros institutions cros hired past listed innovative bioresearch milan italy http www innovativebioresearch com x0csoftware development performing aids cure research important aim project developing xe2 x80 x9cyou xe2 x80 x99re xe2 x80 x9d application developing application professional software development company hired job potential candidates selected listed patacaum willowtree inc xc2 xae dogtownmedia ico partnering innovative bioresearch milan italy http www innovativebioresearch com x0crisk factors purchase innbc token hereinafter article xe2 x80 x9crisk factors xe2 x80 x9d referred token tokens associated high degree risk protect interests tokens xe2 x80 x99 potential purchasers innovative bioresearch hereinafter article xe2 x80 x9crisk factors xe2 x80 x9d referred company team conducted analysis potential risks outlined result analysis chapter whitepaper important list risk factors described exhaustive addition risks disclosed whitepaper existing risks company s team present reasonably forecast risks materialize forms risk specified prior acquiring tokens potential token purchaser advised carefully review information assess risks purchase including limited risks set forth whitepaper decide purchase tokens based assessment 1 technical technological risks 1 1 risks blockchain tokens released ethereum blockchain regard malfunction ethereum protocol lead restriction use tokens fact tokens platform function unforeseen manner 1 2 risk hacker attacks platform smart contracts tokens tokens expropriated stolen hacking tokens hackers groups organizations attempt intervene smart contract tokens ways including limited virus attacks ddos attacks concerted attacks network attacks denial service attacks addition ethereum platform based open source software risk ethereum smart contracts contain intentional unintentional errors shortcomings adversely affect tokens lead loss tokens loss access control tokens event error weakness software remedy tokens owners guaranteed compensation compensation 1 3 risk hacker attack computer tokenholder loss passwords private keys purchased tokens stored tokenholder digital wallet safe password digital key combination digital keys required accordingly loss necessary keys associated digital wallet safe lead loss access tokens addition party gets access passwords private keys way getting hacking negligence tokenholder access login credentials tokenholders hosting wallet able use tokens tokenholder company assumes liability losses 1 4 risk new technologies changes technology future tokens blockchain fairly new relatively untested technologies moment largely proven efficiency reliability security guarantee future technologies innovative bioresearch milan italy http www innovativebioresearch com x0cfail way technological progress develops flaws found technologies flaws prevent functioning way function moment finally guarantee technologies compatible new technologies invented future event incompatibility use tokens blockchain found unreasonable stopped 1 5 risk incompatibility cryptowallet service electronic cryptowallet wallet service provider tokenholder chosen choose obtaining storing tokens technically compatible tokens failure comply condition lead fact tokenholder able access tokens tokenholders independently determine fact compatibility cryptowallet registered tokens company assumes responsibility errors related wrong determination fact 2 regulatory risks 2 1 risk regulatory uncertainty regulatory status cryptographic tokens digital assets blockchain technology unclear defined jurisdictions excluded technologies particular tokens future subject adopted new interpretations laws regulations court judgments actions regulatory bodies world including limited imposition restrictions use possession digital tokens tokens changes adversely affect tokens ways including example determining tokens regulated financial instruments require registration compliance legal requirements procedures company stop distributing tokens developing platform terminating operations particular jurisdiction actions regulatory authorities relevant jurisdiction illegal commercially viable proceed 2 2 risk inability obtain maintain renew licenses permits date tokens sale statutory requirements requiring company obtain licenses permits necessary sale tokens risk legislative requirements enacted future ruled event possibility sale use tokens depend procedure issuing licenses permits compliance terms exclude requirements law technically economically unachievable company company stop distribution tokens develop platform terminate operations particular jurisdiction event economic technological inability obtain required licenses permits jurisdiction 2 3 risk governmental action industry blocking reversing tokens new simply virtue novelty subject increased supervision regulatory control including investigations enforcement actions guarantee government study activities parties investigated turn significant negative impact tokens platform development innovative bioresearch milan italy http www innovativebioresearch com x0c3 business risks 3 1 risk failure development excluded reasons including limited reasons insolvency business technological strategies business arrangements technological problems emergence new technologies etc model company developed described whitepaper achieve desired functionality inoperative work way different developers designed exclude risk different reasons development implementation model longer company predicts moment model ready appear outdated irrelevant 3 2 risk insufficient implementation excluded reasons including limited reasons insolvency marketing strategies external constraints competitors actions model developed company described whitepaper model appear unpopular unclaimed lacking use application 3 3 risk dependence parties launch model developed company described whitepaper rely wholly partially parties adoption implementation certain functions continuing development maintenance support abovementioned parties carefully selected company s team insurance guarantee parties job properly meet users needs significant adverse impact platform 3 4 risk loss cash project described whitepaper model developed xd0 xa1ompany platform created funds collected framework token sale described insured case failure project reason loss functionality token platform private public insurance representative token holders apply reimbursement 3 5 risk force majeure future extraordinary circumstances company reasonably anticipate prevent subject restrictions impediments operation company token platform company performance interrupted suspended delayed force majeure circumstances purposes whitepaper force majeure shall mean extraordinary events circumstances prevented company shall include acts nature wars armed conflicts mass civil disorders industrial actions epidemics lockouts slowdowns prolonged shortage failures energy supplies communication service acts municipal state federal governmental agencies circumstances company s control existence time whitepaper release 3 6 value tokens purchased value tokens significantly fluctuate reasons company guarantee specific value tokens specific period time company shall held responsible change value tokens innovative bioresearch milan italy http www innovativebioresearch com x0c4 risks 4 1 taxes token holders solely responsible determining transactions contemplated subject applicable taxes home country jurisdiction sole responsibility token holders comply tax laws jurisdictions applicable pay relevant taxes 4 2 disclosure information personal information received tokens holders information number tokens owned wallet addresses relevant information disclosed law enforcement government officials parties company required disclose information law subpoena court order company shall time held responsible information disclosure 4 3 risk insufficient information tokens early developmental stage philosophy consensus mechanism algorithm code technical specifications parameters updated changed frequently constantly whitepaper contains date key information related tokens date whitepaper complete final subject adjustments updates company time time company position obliged report detail development tokens elements system presented company necessarily provide timely access information relating tokens use reasonable efforts innovative bioresearch milan italy http www innovativebioresearch com x0c